Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Stable profits, low leverage to keep credit profiles comfortable
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
The Unit currently caters to emerging markets of Latin America and Africa with a variety of dosage forms
The facility will manufacture tablets, capsules, and injections for the oncology segment
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
